ArticleScience progress
Ultrasonographic findings as a prognostic factor in parotid cancer.
Article in Science progress. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
ObjectiveRecent advancements in high-resolution ultrasonography (US) have established it as a critical tool for evaluating parotid lesions. However, the lack of standardized diagnostic criteria limits the utility of US in determining malignancy. This study investigates the potential role of US as a prognostic factor in parotid cancer.MethodsPatients diagnosed with and surgically treated for parotid cancer at our tertiary referral center from January 2016 to December 2022 were included in this retrospective cohort study. We retrospectively obtained patient data including US images and clinical factors and analyzed their correlation with various adverse features and oncological outcomes, including five-year disease-free survival (5Y DFS) and overall survival (5Y OS).ResultsA total of 126 patients were included. The 5Y DFS and 5Y OS were 81.7% ± 3.7% and 81.2% ± 4.1% respectively. Multivariate analysis revealed that age (DFS; HR 2.75 [1.76-4.29],
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.